New analysis shows significant long-term potential in Brighter’s various offers and the company’s share price

Brighter AB [publ],  today announced that Aktiespararna has provided an updated company analysis. 

Included in Aktiespararna’s update is an analysis of the key milestones that Brighter has completed across the company’s three product lines: Actiste®, Camanio and Nectarine Health. 

Brighter signed distribution agreements in three new markets: Ghana, Nigeria and Qatar for Actiste and received market approvals for Actiste® and Actiste® Mini in various regions. The analysis continues to discuss the establishment of a framework agreement with Sweden's Municipalities and Regions for Camanio and it is also noted in the report that Camanio grew its revenue by 88% during Q4 2020. Furthermore, Brighter's subsidiary Nectarine, an innovative AI-based technology to help seniors to live a more full and independent life, is preparing USA launches of its AI-based security alarm in Q3 2021.

An increase in the number of shares in the company after the issue during Q1 2021 is the primary reason for the analyst’s downgrade of the  target share price from his previous guidance of 7.80 to 4.10. 

“We are pleased to read that Aktiespararna sees significant potential in Brighter's shares and various offers in the long term,” stated Christer Trägårdh, acting CEO, Brighter AB.

The entire analysis can be found on Analysguidens website: 

https://www.aktiespararna.se/analysguiden/nyheter/analys-brighter-genombrottsorder-pa-flera-marknader

 

For further information, please contact:

Investor Relations
IR@brighter.se

Christer Trägårdh, Acting CEO
christer.tragardh@brighter.se

Certified Adviser

Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.

About Brighter AB (publ)

Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG

Subscribe

Documents & Links